reducing the risks of chemotherapy in ighv-mutated cll
Published 7 years ago • 488 plays • Length 2:59Download video MP4
Download video MP3
Similar videos
-
1:00
the future of cll treatment: chemotherapy and targeted inhibitors
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:37
a prospective trial of radiation-free chemotherapy in high- and low-risk hl
-
1:36
the changing role of chemotherapy in lymphoma and the value of novel immunotherapies
-
2:31
the role of chemoimmunotherapy in the era of targeted therapies for cll
-
1:29
the importance of treatment sequencing in cll
-
0:43
reducing chemotherapy-induced adverse events in patients with aml
-
4:31
the impact of high and low burden tp53 mutations on risk and treatment decision in cll
-
10:01
2024年 flt3-itd基因突變急性血癌最新治療與成功經驗分享
-
2:47
current treatment options for patients with chronic lymphocytic leukemia (cll)
-
3:13
cll versus other leukemia types
-
2:36
treatment approaches to cll with high-risk molecular features
-
1:01
cll resistance mechanisms in the era of novel agents
-
12:46
fixed duration treatment strategies in cll
-
0:56
the current treatment landscape in cll
-
4:57
sequencing of targeted therapies for cll
-
3:15
should standard chemotherapy regimens be altered in favor of small molecules? ifcg for frontline cll
-
2:19
long-term management of cll for improved outcomes
-
2:49
insights into the role of novel btkis in the treatment landscape of r/r cll
-
2:49
assessing parameters and standardising biomarker detection in cll
-
2:41
fixed-duration vs continuous therapy in cll
-
1:27
what is cll treatment research focused on?